Final Call to Register for BioPartnering Europe (BPE)

LONDON--(BUSINESS WIRE)--There are now just ten days to go until this year’s BioPartnering Europe which will be held on 12^th-14^th October, 2008 at the Queen Elizabeth Conference Centre in London, UK. With nearly 1200 delegates from Europe, the US and Asia now registered to attend, BPE is proving to be as popular as ever, attracting key decision makers from the biotechnology, pharmaceutical and financial industries. This year’s conference aims to not only maximise attendees opportunities to increase their profile within the biotechnology sector, but will also examine key topics facing the industry.

BPE is world-renowned for its unparalleled partnering, networking and financing opportunities. This year BPE will feature:

• Opportunities to meet up with nearly 1200 delegates from Europe, the US and Asia
• 8 Leadership sessions and workshops will discuss some of the most important issues affecting the growth of the life-science industry today
• 180 company presentations from the world’s most innovative companies
• 3 days of unique networking opportunities
• Make the most efficient use of your time by using www.biopartnering.com to set up key meetings in advance

Register online at: www.techvision.com/bpe/registration/

Podium Presentations and Open House Booth Presentations

145 life science companies will offer 13-minute podium presentations over the course of the two days. Presenters will be able to introduce their company, showcase key technologies and highlight partnering goals. Benefits include two conference tickets as well as access to the VIP presenter lounge. The Open House Presentations format features 38 biopharmaceutical and diagnostics companies giving interactive multimedia presentations in specially designed booths. These companies are often looking to partner, out-license, in-license or sell products, technologies or services. The presenters are available during a 2 hour period for informal discussions; followed by 5 hours use of their dedicated meeting booth with the opportunity to schedule meetings directly via the biopartnering.com meeting scheduler.

biopartnering.com now in partnership with Life Science Analytics’ MedTRACK

Don’t miss this incredible opportunity to gather all the market intelligence you will ever need!

Limited complimentary access to MedTRACK via biopartnering.com is only available from September 29th through October 21st by registering for the BioPartnering Europe Conference being held 12-14 October 2008, in London, United Kingdom.

Global Bioscience Partnership Conference Alliance

Technology Vision Group is pleased to announce a partnership with BioEvents that features a conference alliance between BioPartnering Europe 2009 (October 11-13, 2009 – London, UK) and BioSquare 2009 (March 9-11, 2009 – Lyon, France). These events will work together to offer the most valuable conference experience in Europe.

About Technology Vision Group

Technology Vision Group LLC (TVG) is one of the leading business development organizations serving the international life sciences industry. Since 1992, TVG has been developing innovative methods to help life science and associated technology companies attract partners and investors, acquire new products and technologies, and achieve a variety of other strategic business development goals.

Confirmed Presenting Companies:

Ablynx, ACE BioSciences A/S, Aerie Pharmaceuticals, Inc, Addex Pharmaceuticals, Affitech AS/ Affitech USA, Inc., Agile Therapeutics, AlgoNomics NV, Allergy Therapeutics plc, Alligator Bioscience AB, Allozyne, Ambit Biosciences, AM-Pharma B.V., Apthera, Inc., Aquinox Pharmaceuticals Inc., Arana Therapeutics Limited, Archimedes Pharma Ltd, Ardea Biosciences, Asphelia Pharmaceuticals, Asterand UK Limited, Avecia Limited, Balter Inc. (& PhotoSense AS), BaroFold, Inc, Baxter Asia Pacific, Bio Nano Centre, Biocompatibles International plc, Biocontrol Ltd, BioFocus DPI Limited, Biolex Therapeutics, Inc., BioSeek, Inc., BiPar Sciences, Inc, BN ImmunoTherapeutics, BTG, Calabar AB, Celleron Therapeutics, Cellzome Inc., Cequent Pharmaceuticals, Ceregene Inc., Cerenis Therapeutics, Circassia, Clinical Data, CNSBio Pty Ltd, CoLucid Pharmaceuticals, Inc., CoMentis, Inc., Concert Pharmaceuticals, Inc., Critical Pharmaceuticals Ltd, Cumbre Pharmaceuticals Inc., Curis, Inc., Cyclacel Limited, Cytokinetics, Inc., DBV-Technologies, Debiopharm SA, deCODE chemistry & biostructures, Delcath Systems, Inc., Delphi Genetics, e2v biosensors, EcoBiotics Ltd, Egalet a/s, Emergent BioSolutions, Endoceutics, EntreMed, Inc., EquinOx Pharmaceuticals Corporation, Essentialis, Inc., Eurand S.p.A., Evotec, Flamel Technologies SA, f-star Biotechnology, Ganymed Pharmaceuticals AG, Genera Biosystems Limited, Glytech, Haemostatix Ltd, Halozyme Therapeutics, Health Protection Agency, Heptares Therapeutics Ltd, Hyposafe A/S, ImmunoVaccine Technologies Inc. (IVT), Indevus Pharmaceuticals, Inc., Innate Pharma, InNexus Biotechnology Inc., Intas Biopharmaceuticals Ltd, Interleukin Genetics, Inc., Intermune, Inc., Ipsat Therapies Oy, Isconova, Jazz Pharmaceuticals, Inc., KAI Pharmaceuticals Inc., Lamellar Biomedical Limited, Lectus Therapeutics Ltd, Lentigen Corporation, LifeCycle Pharma, Inc., MBC Pharma, Inc, Medelis, Inc., MedPharm Ltd, Menarini Biotech S.r.l., Micromet, Inc., Moberg Derma AB, Modern Biosciences, Molecular Profiles Ltd, MolMed SpA, MorphoSys AG, Napo Pharmaceuticals, Inc., Nektar Therapeutics, NeoGenix Oncology, Inc., Neurobiological Technologies Inc., Neurocrine Biosciences, Inc., Neurotech Pharmaceuticals, NextPharma, Norgine, Novacta Therapeutics, Novosom AG, Novozymes A/S, NsGene A/S, Numerate, Inc., Office of Biomedical Advanced Research and Development Authority (BARDA), Olink Bioscience, Oncolytics Biotech Inc., OptiNose, PharmaNova, PlexPress, PolyMedix Inc., Polytherics, Presidio Pharmaceuticals, Inc., Probiodrug AG, ProCell Therapeutics, Inc./Chonnam National University, Pronota nv, Propanc Pty Ltd, Prosonix Ltd, Protalix Biotherapeutics, Q Chip Ltd, Receptor BioLogix, Revotar Biopharmaceuticals AG, Sciclone Pharmaceuticals, Selvita, SemBioSys Genetics Inc., Sequoia Sciences, Inc., Serodus AS, Serometrix LLC, Shire Pharmaceuticals, Inc., Sidec AB, Silence Therapeutics AG /plc, Simcere Pharmaceutical Incorporation, Spectrum Pharmaceuticals, Inc., Summit plc, SuperGen, Inc., Suven Life Sciences Limited, Symphogen A/S, Synageva BioPharma, Synosia Therapeutics Inc, Syntaxin Ltd, Tetraphase Pharmaceuticals,The University of Nottingham, Therosteon, Theryte Ltd, TopoTarget A/S, Transcept Pharmaceuticals, Transdel Pharmaceuticals, Inc., Tranzyme Pharma, TriStar Technology Group, LLC., Trophos, UCB Group, Vakzine Projekt Management GmbH, ValiBIO SA, Verva Pharmaceuticals Ltd., Vivostat A/S, VLST, Vyteris, Inc., Xenome Ltd., XOMA LTD, YM BioSciences Inc.

Sponsors

AstraZeneca, Deloitte, Takeda Pharmaceuticals, Taylor Wessing, Cooley, Ferghana Partners, Goodwin Procter, Abbott, Amgen, Bristol-Myers Squibb, Glaxo-Smith Kline, International Business Wales, Johnson & Johnson, Merck, Novartis, Pfizer, Procter & Gamble Pharmaceuticals, Roche, UKTI, Farris, Vaughan, Wills and Murphy, ImmuPharma, and Genzyme

Conference Supporters

BioCentury, BioPharm International, BioSquare, Biotech 360, BioWorld Today, Business Wire, Citigate Dewe Rogerson, European Biotechnology News, Nature Publishing Group, The Scientist

GBP Supporters

ap bio, Bay Bio, BIA, BIOCOM, BioEvents, Bio now, ERBI, European Federation of Biotechnology, Federchimica ASSOCBIOTEC, Fundacao Biominas, LifeSciences, Oxfordshire Bioscience Network, British Columbia, UBI France, WBBA